<DOC>
	<DOC>NCT02502123</DOC>
	<brief_summary>This study will prospectively assess long term heath related quality of life in chronic migraine patients currently being treated with OnabotulinumtoxinA for injection (BOTOX®) as standard of care.</brief_summary>
	<brief_title>Patient Reported Outcomes in Patients With Chronic Migraine Treated With BOTOX®</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<criteria>Patients with chronic migraine eligible to receive treatment with onabotulinumtoxinA (BOTOX®) as standard of care. Diagnosis of hemiplegic migraine, basilar migraine, ophthalmoplegic migraine or migrainous infarction, chronic tensiontype headache, hypnic headache, hemicrania continua or new daily persistent headache. Patient who is currently taking or planning on taking opioidcontaining products, barbiturates or combination for acute headache or pain condition. Treatment with any other botulinum toxin product for any condition within 3 months of the screening visit. Diagnosis of myasthenia gravis, EatonLambert syndrome, amyotrophic lateral sclerosis or any other significant disease that might interfere with neuromuscular function.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>